Psoriatic Arthritis
News
Risankizumab impresses in phase 2 psoriatic arthritis trial
From the Journals
Psoriasis therapy with biologics not linked to increased cancer risk
The international case-control study using registry data looked at risk in real-world clinical practice.
Feature
Effects of psoriatic arthritis not just physical
Survey shows impact on patients’ personal lives and their careers.
Conference Coverage
Ixekizumab improves psoriatic arthritis patient-reported outcomes
Ixekizumab improved patient-reported physical function, quality of life, itch score, and work productivity in the SPIRIT-P2 trial.
Conference Coverage
Psoriatic arthritis patients’ cardiovascular risks aren’t spurring increased management
Patients with PsA have a higher risk for cardiovascular morbidity but are managed with the same intensity as the general population.
Conference Coverage
CBC values linked to CVD risk in psoriasis
ORLANDO – Red cell distribution width – a measure of the range of red blood cell volumes in a given sample – and mean platelet volume are...
Conference Coverage
VIDEO: Second wave of psoriatic arthritis therapies
SANDESTIN, FLA. – A new surge of interest in psoriatic arthritis research is underway, which signals an array of new options to target various...
Conference Coverage
Novel x-ray score distinguishes psoriatic arthritis from osteoarthritis of the hand
LIVERPOOL, ENGLAND – The scoring system correctly allocated 100% of images.
Conference Coverage
Family history of psoriasis and PsA predicts disease phenotype
Some rheumatologic family history may predict disease phenotype for psoriasis and psoriatic arthritis.
Conference Coverage
Psoriasis duration reflects cardiovascular event risk
For every year of psoriasis, a patient’s risk of a major cardiovascular event climbs an additional 1%.
Conference Coverage
Is PASI 100 the new benchmark in psoriasis?
KAUAI, HAWAII – “I think we should just do away with PASI 90 and look at how well our drugs do against the metric of PASI 100.”